Xencor president and CEO Dr Bassil Dahiyat noted that Merck’s program is the sixth drug candidate using our XmAb intellectual property currently in clinical trials and is the latest example of its technology offering partners an opportunity to create best-in-class therapeutics.
"By selectively licensing our XmAb technology, we believe we create value in non-core areas, thus allowing us to focus on advancing our key internal development programs," Dr Dahiyat added.
Under the terms of the agreement signed in June 2013, Xencor granted Merck a non-exclusive license to certain Xencor patents for use in an undisclosed product, as well as an option to license the same intellectual property for future products.
Xencor received an upfront payment and continues to receive annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates, as well as royalties on sales of any potential products that may result from this agreement.
In contrast to conventional approaches to antibody design that focus on the Fv domain responsible for binding to target cells, Xencor’s XmAb antibody engineering technology focuses on the Fc domain, the portion of the antibody that interacts with multiple segments of the immune system.
Xencor’s XmAb Fc domains have shown ability in preclinical and clinical studies to enhance antibody performance while typically maintaining over 99.5% identity in structure and sequence to natural antibodies.
This design allows its engineered antibodies to retain the beneficial stability, pharmacokinetics and ease of discovery of natural antibodies, while utilizing validated methods for antibody manufacturing.